A prolonged-release preparation of exenatide has been launched. Bydureon is administered at a dose of 2mg once weekly by subcutaneous injection. Both Bydureon and Byetta, the existing twice-daily preparation of exenatide, are licensed for use in combination with other oral hypoglycaemics in type II diabetes.
Bydureon has been investigated in 1525 patients in 4 key studies: 2 studies comparing exenatide twice daily against once weekly administration; 1 study comparing against sitagliptin or pioglitazone; and 1 study comparing with insulin glargine. Bydureon was more effective at reducing HBA1c levels than comparator treatment in all 4 studies.
Exenatide is contraindicated in renal impairment: Bydureon in patients with creatinine clearance less than 50ml/min; Byetta may be used with caution in these patients but is contraindicated if creatinine clearance is less than 30ml/min.
Further Information: Lilly Eli & Co